Onconews

Revisão do estudo monarchE e valor clínico da expressão do receptor de progesterona no câncer de mama luminal


Listen Later

Referências:

  1. Meirson T, Goldstein DA, Gyawali B, Tannock IF. Review of the monarchE trial suggests
  2. no evidence to support use of adjuvant abemaciclib in women with breast cancer.
    Lancet Oncol. 2023 May 2:S1470-2045(23)00165-1. doi:
    10.1016/S1470-2045(23)00165-1. Epub ahead of print. PMID: 37146621. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00165-1/fulltext
  3. Johnston
  4. SRD, Tolaney SM, O'Shaughnessy J, Rastogi P, Harbeck N, Martin M. Review of the
    monarchE trial suggests no evidence to support use of adjuvant abemaciclib in
    women with breast cancer - Authors' reply. Lancet Oncol. 2023 May
    2:S1470-2045(23)00214-0. doi: 10.1016/S1470-2045(23)00214-0. Epub ahead of
    print. PMID: 37146620. https://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(23)00214-0.pdf
  5. Lashen
  6. AG, Toss MS, Mongan NP, Green AR, Rakha EA. The clinical value of progesterone
    receptor expression in luminal breast cancer: A study of a large cohort with
    long-term follow-up. Cancer. 2023 Apr 15;129(8):1183-1194. doi:
    10.1002/cncr.34655. Epub 2023 Jan 18. PMID: 36653923. https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.34655

     

    ...more
    View all episodesView all episodes
    Download on the App Store

    OnconewsBy onconews